Superficial Bladder Cancer: Intravesical Chemotherapy and Tumour Progression to Muscle Invasion or Metastases
- 1 December 1986
- journal article
- Published by Wiley in BJU International
- Vol. 58 (6), 659-663
- https://doi.org/10.1111/j.1464-410x.1986.tb05907.x
Abstract
Summary— Of 299 patients who presented with superficial bladder cancer (Ta, TI), 60 were treated by intravesical chemotherapy (Epodyl, methotrexate or mitomycin C). The rate of tumour progression to muscle invasion or metastases was identical for each intravesical regime. There was no evidence that mitomycin C promoted tumour progression. Carcinoma in situ in non-tumour-bearing urothelium was the most significant predictive factor for progression to muscle invasion or metastases.Keywords
This publication has 14 references indexed in Scilit:
- Mitomycin C in Superficial Bladder Cancer: 24‐month Follow‐upBJU International, 1985
- The Effect of Intravesical Thiotepa on the Recurrence Rate of Newly Diagnosed Superficial Bladder Cancer. An MRC StudyBJU International, 1985
- DNA/RNA Ratio in Bladder Cancer: a Factor Indicating the Recurrence Rate?BJU International, 1985
- Intravesical Mitomycin C Therapy for Superficial Bladder Cancer. Report of a Multicentre Phase II StudyBJU International, 1985
- Intravesical Methotrexate in the Treatment of Superficial Bladder CancerBJU International, 1984
- Prognostic Significance of Biopsy Results of Normal‐looking Mucosa in Cases of Superficial Bladder CancerBJU International, 1983
- A Phase II Study of lntravesical Mitomycin C in the Treatment of Superficial Bladder CancerBJU International, 1983
- Flat Carcinoma in situ of BladderBJU International, 1975
- A computer program for comparing K samples with right-censored dataComputer Programs in Biomedicine, 1972